SCHEMBL22967375

SCHEMBL22967375

CC(C)Nc1ccc(Oc2ccccn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.49
LTA4H P09960 1/20 0.47
PTGS2 P35354 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
RECQL P46063 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ALOX12 P18054 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KAT2B Q92831 1/20 0.43
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22874621 0.81 PDE10A (0.52) PDE10ALTA4HPTGS2TSHRACACB
SCHEMBL11143982 0.80 PTGS2 (0.57) PDE10ALTA4HPTGS2LMNAKMT2A
SCHEMBL4432434 0.78 KMT2A (0.68) TDP1ALDH1A1LMNAKMT2APOLB
SCHEMBL9973600 0.78 ALDH1A1 (0.50) TDP1RECQLL3MBTL1ALDH1A1LMNA
SCHEMBL10643745 0.78 LTA4H (0.47) PDE10ALTA4HPTGS2KAT2BACACB
SCHEMBL12261852 0.78 NPC1 (0.50) PDE10ALTA4HPTGS2L3MBTL1ALDH1A1
SCHEMBL16792530 0.78 PDE10A (0.52) PDE10ALTA4HPTGS2TDP1LMNA
SCHEMBL13302607 0.77 TDP1 (0.64) LTA4HTDP1RECQLL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL4372004 0.77 PDE10A (0.51) PDE10ALTA4HPTGS2TDP1LMNA
SCHEMBL3530110 0.76 TDP1 (0.54) TDP1RECQLL3MBTL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 PDE10A 826/4885LTA4H 2936/4885PTGS2 2352/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 PDE10A 826/4885LTA4H 2936/4885PTGS2 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.